Neuroepo multisession Phase II and III
Multisession EEG and clinical dataset from a randomized, placebo-controlled study of intranasal NeuroEPO (an erythropoietin formulation) in patients with Parkinson's disease. Participants were assessed at baseline and 9 months after the intervention, with cumulative NeuroEPO dose quantified and placebo coded as zero. The dataset supports analysis of treatment exposure, EEG-derived measures, and motor outcomes (MDS-UPDRS III).
- Participants
- 45
- Channels
- 21 (10-20)
- Size
- 476 MB
- Version
- v1.0.0
- Updated
- Jun 19, 2026